title: Prospects for personalized targeted therapies for cutaneous squamous cell carcinoma.
abstract: Targeted therapies for cutaneous squamous cell carcinoma (cSCC) remain limited. Extensive genetic heterogeneity complicates a robust molecular characterization of the evolution of cSCC. Nonetheless, potential targeted therapies for this cancer are under investigation, including the inhibition of epidermal growth factor receptor (EGFR), which may yield promising results. In addition, the emergence of immune checkpoint blockade therapy and vaccine-based methods may provide novel treatment strategies for cSCC that are tailored to the individual patient. Ultimately, a combination of such methods may yield a multi-pronged targeted approach to personalize the treatment of cSCC.
authors.forename: John C
authors.initials: JC
authors.lastname: Mavropoulos
authors.forename: Bishr
authors.initials: B
authors.lastname: Aldabagh
authors.affiliation: Department of Dermatology, University of California in San Francisco (UCSF) Dermatologic Surgery and Laser Center, UCSF School of Medicine CA USA. Email: arrons@derm.ucsf.edu.
authors.forename: Sarah T
authors.initials: ST
authors.lastname: Arron
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D019496:Cancer Vaccines; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D058990:Molecular Targeted Therapy; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines; D061026:Programmed Cell Death 1 Receptor; C512478:EGFR protein, human; D066246:ErbB Receptors